BOSTON — Method AI, a medical technology company spun out of the Cleveland Clinic, has raised $20 million in Series A financing to accelerate development of its image-guided surgical navigation platform aimed at improving cancer surgery outcomes.
The funding round was led by a private family office with participation from Cleveland Clinic and the JobsOhio Growth Capital Fund. The investment will support the company’s ultrasound-based technology, which is designed to give surgeons a 3D view of anatomy beneath the surface of organs — areas not visible through traditional surgical cameras.
“In complex oncology procedures, surgeons often have to remove tumors that are partially or completely embedded within the organ, making it extremely difficult to gauge the margins of the tumor during a live surgery,” said Doug Teany, co-founder and CEO of Method AI. “This incomplete view of the tumor and other critical anatomy leads to cancer left behind, unforeseen complications, and loss of organ function. With the support of our investment partners, our technology can make the difference between completely removing a tumor or leaving part of it behind, which significantly impacts long-term patient outcomes.”
Method AI’s platform combines continuous 3D ultrasound imaging with real-time algorithms that create subsurface maps and integrate AI-generated surgical plans. The company says the system is designed to guide surgeons through procedures more accurately and could both improve survival rates and reduce complications.
Industry studies estimate that up to 40 percent of surgical oncology procedures fail to fully remove cancer, even with advances in robotic and minimally invasive surgery. Method AI believes its technology could help close that gap and potentially save the healthcare system more than $1 billion annually by reducing repeat surgeries, complications, and long-term treatment costs.
Founded in 2021, the Boston-based company is positioning itself at the intersection of surgical robotics, AI, and medical imaging as it pushes forward with product development and validation.
